Septocaine forte (Articaine + Epinephrine): Uses, Dosage & Side Effects
A dental local anesthetic combining articaine 40 mg/ml (4%) with epinephrine 10 micrograms/ml (1:100,000) for rapid, profound and prolonged anesthesia during dental procedures
Septocaine forte is a sterile, prescription-only dental injection combining the amide-type local anesthetic articaine hydrochloride (40 mg/ml, 4%) with the vasoconstrictor epinephrine (adrenaline) at a concentration of 10 micrograms/ml, corresponding to a 1:100,000 dilution. It is administered exclusively by dental and oral surgery professionals to produce rapid, profound, and relatively long-lasting local and regional anesthesia during dental procedures. Articaine is the most widely used dental local anesthetic in much of Europe, Canada, and Australia, and has become one of the leading agents in the United States since its FDA approval in 2000. The "forte" designation indicates the higher-concentration epinephrine variant (1:100,000), which produces more pronounced vasoconstriction, better hemostasis (reduced bleeding), and slightly deeper or longer anesthesia than the standard 1:200,000 formulation.
Quick Facts: Septocaine forte
Key Takeaways
- Septocaine forte contains articaine hydrochloride 4% (40 mg/ml) combined with epinephrine 1:100,000 (10 micrograms/ml) and is used exclusively for dental and oral surgical procedures, delivering onset of anesthesia within 1–3 minutes and pulpal anesthesia lasting 60–75 minutes.
- Articaine is metabolized predominantly by plasma esterases rather than the liver, giving it a very short plasma half-life of approximately 20 minutes — a pharmacokinetic advantage that contributes to its safety profile even with repeated administration.
- The higher-concentration epinephrine in Septocaine forte (1:100,000 vs. 1:200,000 in standard Septocaine) provides superior hemostasis and can produce slightly deeper or longer anesthesia but increases cardiovascular stimulation, making it less suitable for patients with significant heart disease, uncontrolled hypertension or hyperthyroidism.
- Contraindications include allergy to articaine, other amide anesthetics, or sulfites (sodium metabisulfite preservative); severe cardiac conduction disorders; pheochromocytoma; narrow-angle glaucoma; methemoglobinemia; and G6PD deficiency.
- Septocaine forte is FDA-approved for children aged 4 years and older and is widely used in pediatric dentistry because articaine's diffusion properties often produce effective primary-tooth anesthesia after infiltration alone, avoiding more complex nerve blocks.
What Is Septocaine forte and What Is It Used For?
Septocaine forte is a sterile solution for injection used in dentistry to produce local and regional anesthesia. Each milliliter contains 40 mg of articaine hydrochloride (equivalent to a 4% solution) together with 10 micrograms of epinephrine (also known internationally as adrenaline), yielding an epinephrine concentration of 1:100,000. The solution is supplied in single-use dental cartridges (typically 1.7 ml or 1.8 ml) designed for use with a standard dental aspirating syringe. Administration is performed exclusively by qualified dental practitioners, dental hygienists working under appropriate supervision, oral surgeons and other trained medical professionals.
Articaine is a unique amide-type local anesthetic first synthesized in 1969 by Hoechst Pharmaceuticals in Germany (under the laboratory designation Hoe 40 045) and introduced into European clinical practice in 1976. Unlike all other amide local anesthetics, articaine contains a thiophene ring in place of the benzene ring found in lidocaine, mepivacaine and bupivacaine, and it also incorporates an additional ester side chain. These structural features give articaine two practical advantages: its thiophene ring enhances lipid solubility and tissue penetration, while its ester linkage allows rapid inactivation by plasma esterases in addition to hepatic metabolism. The combined metabolic pathways result in a remarkably short plasma elimination half-life of approximately 20–25 minutes for articaine, compared with roughly 90 minutes for lidocaine and bupivacaine. This rapid clearance is a key reason articaine can be administered repeatedly during long procedures without significant systemic accumulation.
Like all local anesthetics of the amide class, articaine produces anesthesia by binding to voltage-gated sodium channels on the inner surface of nerve cell membranes. When sodium channels are blocked, nerve fibers cannot generate or propagate the electrical impulses (action potentials) that carry pain and other sensory signals to the central nervous system. The blockade is temporary and fully reversible once articaine diffuses away from the nerve and is metabolized. Sensory nerve fibers are generally affected before motor fibers, and small-diameter pain fibers are blocked before larger-diameter touch fibers — which is why patients retain some sense of pressure during dental work even when pain is completely eliminated.
The addition of epinephrine to Septocaine forte serves four important clinical purposes. First, epinephrine is a potent vasoconstrictor: it constricts local blood vessels at the injection site, slowing the systemic absorption of articaine and thereby reducing peak plasma concentrations and the risk of systemic toxicity. Second, slower absorption allows the anesthetic to remain at the nerve for longer, increasing the duration of anesthesia. Third, vasoconstriction reduces bleeding at the operative field, which is particularly useful in surgical dentistry. Fourth, the local vasoconstriction can enhance anesthetic depth, producing the profound anesthesia characteristic of articaine + epinephrine combinations. The "forte" formulation (1:100,000) provides these effects more intensely than the 1:200,000 "standard" formulation.
Septocaine forte is indicated for local and regional anesthesia in dental and oral surgical procedures. Typical clinical uses include:
- Simple tooth extractions: Both in the maxilla (upper jaw) via infiltration and in the mandible (lower jaw) via infiltration or inferior alveolar nerve block.
- Surgical extractions and third-molar (wisdom tooth) removal: Where profound and prolonged anesthesia plus local hemostasis are required.
- Operative dentistry: Cavity preparation, restoration (fillings), crown and bridge preparation, and veneers, where pain-free soft-tissue handling is essential.
- Endodontic therapy (root canal treatment): Providing pulpal anesthesia sufficient for pulp extirpation and canal instrumentation, even in inflamed or hyperemic pulps where anesthesia can be difficult to achieve.
- Periodontal surgery: Flap surgery, gingivectomy, osseous surgery, and guided tissue regeneration, where the hemostatic effect of 1:100,000 epinephrine is particularly valuable.
- Implant surgery: For routine single-implant placements and more complex procedures including bone grafting, where prolonged soft-tissue anesthesia is desirable.
- Minor oral surgery: Apicectomy, biopsy, soft-tissue excision, frenectomy and other intraoral procedures that can be performed under local anesthesia.
- Pediatric dentistry: In children aged 4 years and older, typically using infiltration anesthesia; primary tooth extractions and restorations in young patients.
Articaine with epinephrine 1:100,000 is the most widely used dental local anesthetic in Germany, France, Canada and many other countries, and has become one of the two most commonly used formulations (along with lidocaine 2% with epinephrine 1:100,000) in the United States since articaine received FDA approval in 2000. In large comparative clinical studies and systematic reviews, articaine has demonstrated at least equivalent and often superior maxillary infiltration anesthesia compared to lidocaine, particularly for buccal infiltration of mandibular teeth — a technique that can sometimes substitute for the inferior alveolar nerve block.
Articaine is available with two concentrations of epinephrine: 1:100,000 (as in Septocaine forte) and 1:200,000 (as in standard Septocaine). The 1:200,000 formulation is generally preferred when prolonged soft-tissue anesthesia is not required, when working in patients with mild cardiovascular risk factors, or for routine operative dentistry. The 1:100,000 formulation (forte) is selected when superior hemostasis is needed (surgical procedures), when deep pulpal anesthesia is critical (endodontics, extractions of inflamed teeth), or when longer-duration soft-tissue anesthesia is an advantage. Both formulations contain identical articaine concentrations (4%).
What Should You Know Before Receiving Septocaine forte?
Contraindications
There are several clinical situations in which Septocaine forte must not be used. These absolute contraindications reflect the combined risks of articaine, epinephrine, and the excipients in the injection solution.
- Allergy to articaine or other amide local anesthetics: Do not use Septocaine forte if you have a confirmed hypersensitivity to articaine hydrochloride, to any other amide-type local anesthetic (such as lidocaine, mepivacaine, prilocaine, bupivacaine, ropivacaine or etidocaine), or to any of the excipients. True amide allergy is rare but can be severe.
- Allergy to sulfites: Septocaine forte contains sodium metabisulfite as an antioxidant to protect the epinephrine. Sulfites can provoke severe allergic-type reactions including anaphylaxis and asthma exacerbations in sensitive individuals, particularly in some asthmatic patients. Patients with known sulfite allergy must not receive Septocaine forte.
- Severe cardiovascular disease: Septocaine forte is contraindicated in unstable angina, recent myocardial infarction (within six months), recent coronary artery bypass surgery, severe uncontrolled hypertension, severe arrhythmias (particularly paroxysmal tachycardia), high-degree atrioventricular block without a pacemaker, decompensated heart failure, and severe hypotension.
- Pheochromocytoma: A rare catecholamine-secreting adrenal tumor; exogenous epinephrine can precipitate a hypertensive crisis.
- Uncontrolled hyperthyroidism: Thyroid excess sensitizes the heart and vasculature to catecholamines, potentiating the effects of epinephrine.
- Narrow-angle (closed-angle) glaucoma: Epinephrine can precipitate an acute angle-closure attack.
- Methemoglobinemia: Patients with congenital or acquired methemoglobinemia should not receive articaine, which has been associated with elevations in methemoglobin.
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency: These patients are at increased risk of methemoglobinemia and hemolysis following articaine exposure.
- Severe liver disease: Although articaine is primarily cleared by plasma esterases, severe hepatic impairment can still prolong its elimination; case-by-case evaluation is required.
- Children under 4 years of age: Safety and efficacy have not been established.
Warnings and Precautions
Dental anesthetic injections carry a small but important risk of accidental intravascular (into a blood vessel) administration, which can cause rapid systemic toxicity including seizures and cardiovascular collapse. Practitioners reduce this risk through careful injection technique, slow administration, and aspirating before and during injection to confirm the needle tip is not inside a blood vessel.
Even in the absence of absolute contraindications, the following conditions require caution and may modify the choice of anesthetic or technique:
- Moderate cardiovascular disease: Stable angina, well-controlled hypertension, prior myocardial infarction (more than six months ago), pacemaker in situ, or rate-controlled atrial fibrillation. In such patients, the total epinephrine dose is limited (commonly to about 40 micrograms per session, corresponding to approximately 4 ml of Septocaine forte), aspiration is mandatory, and concurrent use of other vasoconstrictors (e.g., gingival retraction cord containing epinephrine) should be avoided.
- Diabetes mellitus: Epinephrine can transiently increase blood glucose. Diabetic patients should monitor their glucose levels following more extensive procedures. Avoid large doses in brittle diabetes.
- Renal impairment: Although renal clearance of articaine is minor, the monocarboxylic acid metabolite (articainic acid) is renally eliminated and may accumulate in severe renal failure.
- Acute intermittent porphyria: Local anesthetics are generally considered safe in porphyria, but caution is warranted.
- Cholinesterase deficiency: Because articaine is hydrolyzed by plasma esterases, patients with pseudocholinesterase deficiency may have prolonged articaine effects; case reports have documented delayed recovery from anesthesia.
- Elderly patients and debilitated individuals: May have reduced plasma esterase activity, reduced hepatic clearance, and increased cardiovascular susceptibility; use the lowest effective dose.
- Inflamed or infected tissue: Local anesthetic efficacy is reduced in acidic inflamed tissue, and vasodilation may increase systemic absorption. Avoid injection directly into infected areas.
Soft-tissue numbness of the lips, cheek, and tongue may persist for 3 to 5 hours after a mandibular nerve block with Septocaine forte. During this period, patients (particularly young children and cognitively impaired individuals) may inadvertently bite their lips, cheek or tongue, causing significant soft-tissue injury. Caregivers should supervise eating and avoid hot food or drink until sensation returns fully.
Pregnancy and Breastfeeding
Pregnancy is not an absolute contraindication to Septocaine forte, and untreated dental infection or severe dental pain can itself pose risks to mother and fetus (including systemic infection, poor nutrition, and maternal stress). Articaine crosses the placenta by passive diffusion, but the placenta also metabolizes articaine, limiting fetal exposure. Small epinephrine doses used in dental anesthesia do not typically produce clinically important uterine vasoconstriction. The American College of Obstetricians and Gynecologists (ACOG) and the American Dental Association (ADA) both support the use of local anesthetics with epinephrine for necessary dental procedures during pregnancy. When elective treatment is possible, the second trimester is generally preferred; urgent treatment should proceed when clinically required with appropriate medical consultation.
Small amounts of articaine and its metabolite articainic acid are excreted into breast milk, and even smaller amounts of epinephrine (which is also endogenous) appear in milk. At the doses typically administered for dental procedures, these amounts are clinically insignificant, and the drugs are rapidly cleared. Septocaine forte is therefore considered compatible with breastfeeding. Nursing mothers do not need to interrupt breastfeeding after dental anesthesia with articaine.
Important Information About Excipients
Septocaine forte contains sodium metabisulfite as an antioxidant to prevent oxidation of epinephrine. Sulfites can cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible individuals. The overall prevalence of sulfite sensitivity in the general population is unknown but is generally low and probably higher in asthmatic than non-asthmatic individuals. If you have a history of sulfite sensitivity, inform your dentist, who may select a sulfite-free formulation of articaine (available without a vasoconstrictor and therefore without the need for metabisulfite).
Septocaine forte also contains sodium chloride (for isotonicity) and small amounts of sodium hydroxide and/or hydrochloric acid for pH adjustment. It does not contain parabens or latex in the cartridge closures of most modern preparations, but patients with significant latex allergy should confirm the specific cartridge brand in use.
Driving and Operating Machinery
Septocaine forte acts locally and has no central depressant effect at therapeutic doses. Patients can generally drive and operate machinery immediately after a dental procedure, provided they feel well and have no dizziness or residual effects from sedation (if used). If larger doses are required, if you feel lightheaded or shaky after the injection (usually due to transient epinephrine effects or anxiety), wait until you feel completely normal before driving. The persistent numbness of the lips and tongue does not impair driving.
How Does Septocaine forte Interact with Other Drugs?
Although the total dose of articaine and epinephrine delivered during a typical dental appointment is small, several pharmacologically important drug interactions can still occur, particularly with multiple injections or in susceptible patients. Always provide your dental professional with a complete list of all prescription medications, over-the-counter drugs, herbal products and recreational substances. The interactions below relate primarily to the epinephrine (vasoconstrictor) component, with a few that relate to articaine itself.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Non-selective beta-blockers (propranolol, nadolol, timolol, sotalol) | Non-selective beta-blockade leaves unopposed alpha-adrenergic action of epinephrine, causing paradoxical severe hypertension and reflex bradycardia after injection | Limit the total dose of epinephrine to a minimum. Aspirate carefully and inject slowly. Cardioselective beta-blockers (metoprolol, bisoprolol, atenolol) interact less strongly. Monitor blood pressure. |
| Tricyclic antidepressants (amitriptyline, nortriptyline, imipramine) | TCAs inhibit reuptake of catecholamines at adrenergic synapses, potentiating the pressor effects of epinephrine and potentially causing dangerous increases in blood pressure and arrhythmias | Use the lowest effective dose of epinephrine; consider an articaine preparation with 1:200,000 epinephrine instead of forte. Avoid large cumulative doses and monitor hemodynamic response. |
| Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide) | MAOIs reduce the degradation of endogenous and exogenous catecholamines, potentially exaggerating the cardiovascular effects of injected epinephrine | While low doses of injected epinephrine in dental practice are generally tolerated, caution is advised. Prefer the lowest effective epinephrine concentration and monitor blood pressure closely. |
| Halogenated inhalation anesthetics (halothane, enflurane, isoflurane, sevoflurane) | These volatile anesthetic gases sensitize the myocardium to catecholamines, increasing the risk of ventricular arrhythmias when epinephrine is injected during general anesthesia | This interaction is relevant primarily to oral surgery under general anesthesia. The anesthesiologist must be informed; dose limits for infiltrated epinephrine apply. |
| Cocaine | Cocaine blocks catecholamine reuptake and directly stimulates the cardiovascular system; concurrent use with epinephrine produces additive or synergistic effects and marked risk of hypertensive crisis, arrhythmia and myocardial infarction | Elective dental procedures should be deferred for at least 24 hours (preferably 48–72 hours) after any cocaine use. If urgent treatment is required, avoid epinephrine-containing anesthetics. |
| Other local anesthetics | Systemic toxicity of local anesthetics is additive. Concurrent or sequential use of different local anesthetic formulations in the same session (e.g., articaine plus lidocaine) can push total exposure above safe thresholds | Track the total cumulative dose of all local anesthetics. Stay within the combined maximum safe dose, calculated on a milligram-per-kilogram basis. |
Minor and Notable Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Phenothiazines and butyrophenones (chlorpromazine, haloperidol) | These agents have alpha-adrenergic blocking activity and may partially antagonize the pressor effects of epinephrine, rarely producing paradoxical hypotension | Be aware of possible hypotension rather than hypertension. Monitor blood pressure; use the smallest effective dose of epinephrine. |
| Thyroid hormones (levothyroxine) in excess | Hyperthyroidism (iatrogenic or disease-related) sensitizes cardiovascular receptors to catecholamines, amplifying the effects of injected epinephrine | Avoid or minimize Septocaine forte in uncontrolled hyperthyroidism; the standard (1:200,000) formulation or plain mepivacaine may be preferable. |
| Oxytocin and ergot derivatives | Combined administration with sympathomimetics can produce severe or persistent hypertension, and in the case of ergot alkaloids, rupture of cerebral blood vessels has been reported | Avoid concurrent use of ergot derivatives with epinephrine-containing local anesthetics. Dental treatment should be scheduled away from obstetric administration. |
| Drugs that cause methemoglobinemia (benzocaine, nitrates, dapsone, sulfonamides, prilocaine) | Articaine has been associated (rarely) with methemoglobinemia; concurrent use with other oxidizing agents increases this risk, particularly at high cumulative doses | Avoid combining articaine with other methemoglobinemia-inducing drugs within a short interval. Monitor for cyanosis, shortness of breath, and fatigue. |
| Class I and III antiarrhythmics (mexiletine, amiodarone, sotalol) | Additive effects on cardiac sodium channels and conduction may potentiate the cardiotoxic potential of articaine | Use the minimum effective dose of articaine. Monitor cardiac rhythm in patients with arrhythmia history. |
What Is the Correct Dosage of Septocaine forte?
Dosing of Septocaine forte is individualized by the treating dentist based on the nature and duration of the planned procedure, the area to be anesthetized, the depth and duration of anesthesia required, vascularity of the injection site, the patient's physical condition, age, and weight. The doses below are based on the FDA-approved US prescribing information, EMA Summary of Product Characteristics and the BNF Dental Practitioners' Formulary. They are guidance only and do not substitute for professional clinical judgment.
Adults
Septocaine forte (Articaine 4% with Epinephrine 1:100,000)
Simple tooth extraction (upper jaw): Usually 0.9–1.8 ml (36–72 mg articaine) per tooth by supraperiosteal infiltration. Additional small volumes may be needed for palatal anesthesia.
Simple tooth extraction (lower jaw): Usually 1.8 ml (72 mg articaine) for a mandibular nerve block, supplemented with 0.9 ml buccal infiltration if needed.
Surgical or complex extraction: 1.0–4.0 ml (40–160 mg articaine), titrated to clinical effect.
Operative dentistry (fillings, crowns): 0.5–1.8 ml (20–72 mg articaine) per tooth via infiltration.
Maximum single-session dose in adults: 7 mg/kg body weight (articaine), not to exceed 500 mg total. For a 70 kg adult, this corresponds to approximately 12.5 ml of Septocaine forte (about 7 dental cartridges).
| Procedure | Typical Volume | Articaine Dose / Notes |
|---|---|---|
| Maxillary infiltration (single tooth) | 0.9–1.8 ml | 36–72 mg; onset 1–3 min; pulpal anesthesia ~60 min |
| Mandibular nerve block | 1.5–1.8 ml | 60–72 mg; onset 2–5 min; pulpal anesthesia ~90–120 min |
| Buccal infiltration (mandibular molar) | 1.8 ml | 72 mg; articaine may anesthetize mandibular molars via buccal infiltration |
| Surgical third-molar extraction | 2.0–4.0 ml | 80–160 mg; combined block and infiltration; hemostasis benefit |
| Periodontal flap surgery | 2.0–5.0 ml | 80–200 mg; 1:100,000 epinephrine optimizes hemostasis |
| Endodontic (root canal) treatment | 1.8–3.6 ml | 72–144 mg; may require supplemental intraligamentary or intraosseous injection in irreversible pulpitis |
Children (4 Years and Older)
Septocaine forte is approved for use in children aged 4 years and older in most jurisdictions. Children are generally dosed on a milligram-per-kilogram basis, with the maximum cumulative articaine dose limited to 7 mg/kg body weight (and never exceeding the adult maximum of 500 mg). A pediatric dental cartridge contains approximately 68 mg articaine (for a 1.7 ml cartridge), so a 20 kg child has an approximate maximum of 140 mg articaine per session (about 2 cartridges of Septocaine forte). In practice, typical pediatric doses are much smaller than this ceiling — often only a fraction of a cartridge for a single restoration. Articaine's excellent diffusion means that maxillary and primary-tooth mandibular restorations can frequently be anesthetized by infiltration alone, avoiding the need for an inferior alveolar nerve block. Safety and effectiveness in children under 4 years of age have not been established, and Septocaine forte must not be used in this age group.
Elderly and Medically Compromised Patients
Older adults are more susceptible to both the cardiovascular effects of epinephrine and the systemic effects of articaine. Age-related reductions in plasma cholinesterase activity, hepatic perfusion and cardiovascular reserve make elderly patients more sensitive to local anesthetic toxicity. Start with the lowest effective dose, inject slowly, aspirate before injection, and consider whether a 1:200,000 epinephrine formulation or a plain local anesthetic would be more appropriate. In medically compromised patients (significant cardiovascular disease, severe hepatic or renal impairment, advanced age), the total epinephrine dose is often restricted to 40 micrograms per appointment, which corresponds to approximately 4 ml of Septocaine forte.
Missed Dose
Because Septocaine forte is administered only by professionals during a specific procedure, there is no concept of a "missed dose." Patients do not self-administer this medicine.
Overdose
Systemic toxicity from local anesthetics (known as LAST — Local Anesthetic Systemic Toxicity) is a rare but potentially life-threatening complication. If you experience numbness around the mouth far from the injection site, dizziness, tinnitus, metallic taste, visual disturbances, muscle twitching, palpitations, or difficulty breathing during or shortly after a dental injection, tell your dental team immediately.
Systemic articaine toxicity occurs when blood concentrations reach the threshold for central nervous system and cardiovascular effects — typically only after accidental intravascular injection or after doses that exceed the maximum recommended limits. Because articaine is rapidly metabolized by plasma esterases (half-life ~20 minutes), toxicity tends to be shorter-lived than with lidocaine or bupivacaine.
Early warning symptoms include perioral numbness (beyond the expected area), a metallic taste, tinnitus, auditory hypersensitivity, dizziness, lightheadedness, visual disturbances, restlessness, and anxiety. Progressive toxicity produces slurred speech, muscle twitching, tremor, confusion and ultimately tonic-clonic seizures. Severe toxicity causes CNS depression (drowsiness, respiratory depression, coma) and cardiovascular toxicity (bradycardia, hypotension, conduction block, ventricular arrhythmias, cardiac arrest). Epinephrine overdose itself (usually from multiple injections or inadvertent intravascular injection) produces tachycardia, severe hypertension, palpitations, headache, tremor and, rarely, myocardial ischemia or cerebrovascular events.
Treatment of LAST is supportive and follows international guidelines (including ASRA and AAGBI recommendations): stop the injection, call for help, secure the airway and provide oxygen, control seizures with benzodiazepines, support the circulation, and administer intravenous 20% lipid emulsion ("lipid rescue") according to the protocol if severe cardiovascular toxicity is present. Dental facilities in which local anesthetics are administered must maintain emergency drugs and equipment, including lipid emulsion or the ability to transfer patients rapidly.
What Are the Side Effects of Septocaine forte?
Like all medicines, Septocaine forte can cause side effects, although not everyone gets them. Most reactions are mild and transient. Adverse effects can be broadly divided into three categories: (1) local effects at or near the injection site, (2) systemic effects of articaine, and (3) systemic effects of epinephrine. The frequency categories below are based on manufacturer product information, regulatory documents and published post-marketing surveillance data.
Very Common
- Expected numbness: Temporary loss of sensation in the treated area, lips, tongue and cheek — the intended therapeutic effect
- Injection-site discomfort: Brief, mild pain or pressure during injection
Common
- Headache after the procedure
- Transient palpitations or awareness of a rapid heartbeat (from epinephrine)
- Mild anxiety, shakiness or trembling, usually resolving within minutes
- Local bruising (hematoma) at the injection site
- Post-procedural soreness or stiffness of the jaw, particularly after nerve blocks
- Paresthesia (tingling, pins and needles sensation) that resolves spontaneously
Uncommon
- Nausea or vomiting
- Dizziness or lightheadedness
- Hypertension (elevated blood pressure), usually mild and transient
- Bradycardia or tachycardia
- Facial flushing or pallor
- Self-inflicted lip, cheek or tongue trauma during the period of numbness (particularly in children)
- Transient blurred vision or double vision (if the local anesthetic diffuses near the orbit)
Rare
- Allergic and hypersensitivity reactions: Skin rash, urticaria (hives), itching, angioedema (swelling of lips, tongue or throat), bronchospasm, and rarely anaphylaxis. May be triggered by articaine or by the sulfite preservative
- Persistent paresthesia: Prolonged numbness or altered sensation of the lip, tongue or chin after mandibular nerve blocks, sometimes lasting weeks or months; in most cases it resolves
- Methemoglobinemia: Rare elevation of methemoglobin causing cyanosis (bluish discoloration), fatigue, shortness of breath, headache; managed with methylene blue if clinically significant
- Chest pain or angina: Usually in patients with underlying coronary artery disease, triggered by epinephrine
- Hypertensive crisis: Markedly elevated blood pressure, particularly in patients on non-selective beta-blockers or with uncontrolled hypertension
Very Rare / Frequency Not Known
- Anaphylactic shock
- Seizures (convulsions), usually associated with accidental intravascular injection or overdose
- Respiratory depression or apnea
- Ventricular arrhythmias, cardiac arrest
- Ocular complications (diplopia, temporary blindness, ophthalmoplegia) from inadvertent arterial or retrograde anesthetic flow
- Facial nerve palsy (Bell's palsy-like) after inferior alveolar block, usually transient
- Injection-site necrosis or sloughing, very rare, more likely when injected under excessive pressure or into mucosa with compromised blood supply
- Osteonecrosis of the jaw has been reported very rarely with intraligamentary injections of vasoconstrictor-containing local anesthetics
Call emergency services or go to the emergency department right away if you develop after a dental injection: severe swelling of the face, lips, tongue or throat; difficulty breathing, wheezing or chest tightness; widespread rash with hives; chest pain, severe palpitations or fainting; severe headache with blurred vision (possible hypertensive crisis); seizure or loss of consciousness; or cyanosis (bluish skin) with shortness of breath (possible methemoglobinemia).
It is important to distinguish the expected local numbness of the treated area — which is the intended effect of the anesthetic — from abnormal systemic sensations such as numbness spreading to distant areas of the face, metallic taste, ringing in the ears or muscle twitching. The former is normal; the latter suggests systemic absorption of articaine beyond the therapeutic threshold and warrants immediate evaluation.
If you experience any adverse effect following dental anesthesia with Septocaine forte, even if it is not listed above, report it to your dentist. You (or your dentist) can also submit a report to the national pharmacovigilance authority — for example, the MHRA Yellow Card scheme in the United Kingdom, the FDA MedWatch program in the United States, or the EudraVigilance system in the European Union. Spontaneous reporting helps maintain ongoing monitoring of medicine safety.
How Should Septocaine forte Be Stored?
Because Septocaine forte is stocked and administered in dental clinics, storage is primarily the responsibility of the healthcare facility. Nevertheless, patient-facing information about storage helps with understanding how the medicine's stability is preserved and why certain precautions are necessary.
- Temperature: Store at room temperature below 25°C (77°F). Do not refrigerate and do not freeze. Exposure to freezing temperatures can damage the cartridge and alter the solution.
- Protection from light: Keep cartridges in the original carton or blister packaging until immediately before use. Epinephrine is particularly sensitive to light and oxidation, which is why sodium metabisulfite is added as an antioxidant.
- Inspection before use: Before each injection, the dental professional inspects the cartridge. The solution should be clear and colorless. A pinkish, yellow or brown discoloration indicates oxidation of the epinephrine and the cartridge must be discarded. Cloudy solutions, visible particles, damaged rubber stoppers, cracked glass or a missing aluminum seal are also reasons to discard.
- Expiry date: Do not use Septocaine forte after the expiry date stated on the carton and cartridge. The expiry date refers to the last day of the stated month.
- Single-patient use: Each dental cartridge is intended for single-patient use only. Any unused solution remaining in a partially used cartridge must be discarded with the needle at the end of the appointment — it cannot be saved for later use on the same or another patient.
- Sharps disposal: Used cartridges, needles, and syringes must be disposed of in designated sharps containers in accordance with local medical waste regulations.
- Child safety: Although Septocaine forte is stored in healthcare facilities rather than homes, all medicines and medical supplies should be kept out of the sight and reach of children.
- Environmental disposal: Do not dispose of medications via household waste or wastewater. Return unused Septocaine forte to the pharmacy or medical waste authority for proper disposal.
What Does Septocaine forte Contain?
Septocaine forte is supplied as a sterile, isotonic, aqueous solution in single-use dental cartridges (typically 1.7 ml or 1.8 ml) designed for use with standard dental aspirating syringes. The formulation is carefully balanced to deliver effective anesthesia while preserving the stability of both active components.
Active Ingredients
Each milliliter of Septocaine forte contains:
- Articaine hydrochloride 40.0 mg — the amide-type local anesthetic that produces nerve conduction block and anesthesia. Articaine is (RS)-methyl 4-methyl-3-[2-(propylamino)propionamido]thiophene-2-carboxylate hydrochloride.
- Epinephrine 10 micrograms, supplied as epinephrine tartrate or epinephrine bitartrate — the sympathomimetic vasoconstrictor that produces local vasoconstriction, prolongs anesthetic action, reduces systemic absorption, and provides hemostasis. This concentration corresponds to a 1:100,000 dilution of epinephrine.
Inactive Ingredients (Excipients)
- Sodium metabisulfite (typically 0.5–0.6 mg/ml) — an antioxidant that protects epinephrine from oxidation during storage. This is the ingredient most commonly implicated in allergic-type reactions to articaine-epinephrine preparations.
- Sodium chloride — used to make the solution isotonic (similar salt concentration to body fluids), improving patient comfort during injection.
- Sodium hydroxide and/or hydrochloric acid — added in small quantities to adjust the pH of the final solution. Solutions containing epinephrine have a slightly acidic pH (typically 3.0–4.5) because epinephrine is stable under mildly acidic conditions. The low pH contributes to the brief stinging sensation that some patients feel during injection.
- Water for injections — the solvent.
Septocaine forte contains sodium metabisulfite. Sulfites can cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Sulfite sensitivity is generally uncommon but may be more frequent in patients with severe asthma. Inform your dental professional of any sulfite allergy before treatment.
Appearance and Packaging
Appearance: Septocaine forte is a clear, colorless or very slightly tinged, particle-free sterile solution.
Primary packaging: Glass cartridges typically containing 1.7 ml or 1.8 ml of solution, sealed at one end with an aluminum cap over a rubber membrane, and at the other with a rubber plunger. Modern cartridges use latex-free rubber components and a glass barrel; cartridges are supplied in cardboard trays and boxed cartons of 10, 50 or 100.
Secondary packaging: Cartons labeled with the lot number, expiry date and storage instructions, intended for dispensing to qualified dental and medical professionals.
Related Formulations and Brand Names
Articaine hydrochloride 4% with epinephrine is marketed worldwide under a variety of brand names. In addition to Septocaine forte, commonly encountered products containing articaine 40 mg/ml with epinephrine 10 micrograms/ml (1:100,000) include Septanest SP 1:100,000, Ultracain D-S forte, Zorcaine forte and Articadent forte. The standard-concentration counterpart with epinephrine 5 micrograms/ml (1:200,000) is sold as Septocaine, Septanest SP 1:200,000, Ultracain D-S and similar names. Plain articaine (without vasoconstrictor) is available for use in patients in whom epinephrine is contraindicated.
Marketing authorization: The worldwide manufacturer and originator of several articaine brands is Septodont (Saint-Maur-des-Fossés, France); licensed generics are manufactured by multiple companies. The marketing authorization holder varies by country; consult the specific package insert or summary of product characteristics for locally relevant information.
Frequently Asked Questions About Septocaine forte
Septocaine forte is a dental local anesthetic containing articaine 40 mg/ml (4%) with epinephrine (adrenaline) 10 micrograms/ml (1:100,000). It is administered by dentists and oral surgeons to produce local and regional anesthesia for dental procedures including simple and complex tooth extractions, cavity preparations, crown and bridge work, root canal treatment, periodontal surgery, and minor oral surgery. The added epinephrine prolongs anesthetic action and reduces bleeding at the operative site.
Both products contain articaine hydrochloride 40 mg/ml (4%), but they differ in the concentration of the vasoconstrictor epinephrine. Septocaine (standard) contains epinephrine 1:200,000 (5 micrograms/ml), while Septocaine forte contains epinephrine 1:100,000 (10 micrograms/ml). The "forte" (higher) epinephrine concentration provides more pronounced vasoconstriction, which produces better hemostasis (less bleeding) and may give slightly longer or deeper anesthesia, but carries a higher risk of cardiovascular side effects. Both formulations are routinely used in dental practice; the choice depends on the procedure and the patient's cardiovascular status.
The duration of anesthesia from Septocaine forte depends on the injection technique. For infiltration anesthesia (such as in the upper jaw), pulpal (tooth) anesthesia lasts approximately 60 to 75 minutes, and soft-tissue numbness (lips, cheeks, tongue) may persist for 3 to 5 hours. For mandibular (lower jaw) nerve blocks, pulpal anesthesia lasts approximately 90 minutes to 2 hours, with soft-tissue anesthesia extending up to 5 hours. Onset of action is rapid, typically within 1 to 3 minutes of injection. The prolonged soft-tissue numbness is why patients are advised not to eat, drink hot liquids, or chew gum until sensation returns.
Septocaine forte contains epinephrine, which can increase heart rate and blood pressure. Most patients with stable, well-controlled cardiovascular disease can safely receive articaine with epinephrine 1:100,000 in limited doses. However, Septocaine forte is contraindicated in patients with unstable angina, recent myocardial infarction (within 6 months), severe uncontrolled hypertension, severe cardiac arrhythmias, decompensated heart failure, pheochromocytoma, and uncontrolled hyperthyroidism. In patients with moderate cardiovascular disease, the standard formulation with epinephrine 1:200,000 or a plain articaine solution without vasoconstrictor may be preferred. Always inform your dentist about all heart conditions and medications before receiving dental anesthesia.
Articaine with epinephrine has been widely used in pregnant patients for necessary dental procedures and is generally considered acceptable when the benefit outweighs the risk. The American Dental Association (ADA) and the American College of Obstetricians and Gynecologists (ACOG) support the use of local anesthetics with epinephrine for pregnant patients when dental treatment cannot safely be postponed. Articaine crosses the placenta; however, elective dental procedures should ideally be deferred until after delivery. When dental treatment is necessary, the second trimester is generally considered the safest period. Articaine also passes into breast milk in small amounts and is considered compatible with breastfeeding at normal therapeutic doses.
Articaine 4% with epinephrine 1:100,000 (Septocaine forte) is approved for children 4 years of age and older in the United States and in the European Union. It is widely used in pediatric dentistry because articaine produces excellent anesthesia for primary teeth via infiltration, often avoiding the need for more complex nerve blocks. Safety and effectiveness have not been established in children under 4 years, and Septocaine forte should not be used in this age group. Pediatric doses are carefully calculated based on body weight, with a maximum recommended dose of 7 mg/kg (never exceeding the adult maximum). Total injection volumes are kept small to avoid systemic toxicity.
Most patients tolerate Septocaine forte without significant problems. However, potential adverse reactions include signs of systemic articaine toxicity (numbness around the mouth, metallic taste, ringing in the ears, dizziness, visual disturbances, tremors, seizures), epinephrine-related cardiovascular effects (palpitations, rapid heart rate, elevated blood pressure, anxiety, chest pain), and allergic reactions (rash, hives, swelling, difficulty breathing). Rarely, articaine has been associated with methemoglobinemia (bluish skin, shortness of breath) and persistent paresthesia (long-lasting numbness) after mandibular nerve blocks. Seek immediate medical attention if you experience chest pain, severe shortness of breath, severe swelling, fainting, or seizures following dental anesthesia.
It is recommended to wait until the numbness fully resolves before eating solid food or drinking hot liquids. This typically takes 3 to 5 hours after a mandibular nerve block and 1 to 3 hours after maxillary infiltration. During the numb period, you cannot reliably feel heat or texture, so you risk burning yourself on hot drinks or accidentally biting your cheek, lip or tongue. Cool or room-temperature drinks are usually safe. If you must eat, stick to soft foods and chew on the non-numb side of your mouth. Children should be supervised closely during this period to prevent self-inflicted bite injuries.
References
This article is based on current international medical guidelines, regulatory documents, and peer-reviewed research. All sources meet evidence level 1A standards.
- U.S. Food and Drug Administration (FDA). Septocaine (articaine hydrochloride and epinephrine injection) – Full Prescribing Information. Silver Spring, MD: FDA; 2024. Approved labeling including pharmacology, clinical studies, adverse reactions, and pediatric use.
- European Medicines Agency (EMA). Articaine Hydrochloride with Epinephrine 1:100,000 – Summary of Product Characteristics. Amsterdam: EMA/CHMP; 2024. Regulatory document covering indications, dosing, contraindications and safety data.
- Joint Formulary Committee. British National Formulary (BNF) – Articaine Hydrochloride Monograph and Dental Practitioners' Formulary. London: BMJ Group and Pharmaceutical Press; 2024. Evidence-based prescribing reference for UK healthcare professionals.
- Malamed SF, Gagnon S, Leblanc D. Efficacy of articaine: a new amide local anesthetic. Journal of the American Dental Association. 2000;131(5):635–642. doi:10.14219/jada.archive.2000.0237
- Malamed SF. Handbook of Local Anesthesia. 7th ed. St. Louis, MO: Elsevier; 2019. Comprehensive reference on dental local anesthetic pharmacology, techniques and complications.
- Snoeck M. Articaine: a review of its use for local and regional anesthesia. Local and Regional Anesthesia. 2012;5:23–33. doi:10.2147/LRA.S16682
- Kung J, McDonagh M, Sedgley CM. Does articaine provide an advantage over lidocaine in patients with symptomatic irreversible pulpitis? A systematic review and meta-analysis. Journal of Endodontics. 2015;41(11):1784–1794. doi:10.1016/j.joen.2015.07.001
- Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity Checklist: 2020 Version. Regional Anesthesia and Pain Medicine. 2021;46(1):81–82. doi:10.1136/rapm-2020-101986
- Association of Anaesthetists of Great Britain and Ireland. Management of Severe Local Anaesthetic Toxicity: AAGBI Safety Guideline. London: AAGBI; 2020. Recognition and treatment of local anesthetic toxicity, including lipid emulsion rescue protocol.
- American Dental Association (ADA) Council on Scientific Affairs. Pharmacological management of dental pain and anxiety in children and adults. Chicago, IL: ADA; 2023. Guidance on the use of local anesthetics including articaine with epinephrine.
- Garisto GA, Gaffen AS, Lawrence HP, Tenenbaum HC, Haas DA. Occurrence of paresthesia after dental local anesthetic administration in the United States. Journal of the American Dental Association. 2010;141(7):836–844. doi:10.14219/jada.archive.2010.0281
- Oertel R, Rahn R, Kirch W. Clinical pharmacokinetics of articaine. Clinical Pharmacokinetics. 1997;33(6):417–425. doi:10.2165/00003088-199733060-00002
Editorial Team
This article has been written and reviewed by the iMedic medical editorial team according to our strict editorial standards. Our team consists of licensed physicians, dentists, pharmacists, and medical researchers with expertise in dental anesthesiology, clinical pharmacology, and drug safety.
Content developed by iMedic's medical writing team based on current international guidelines (FDA, EMA, BNF, ADA) and peer-reviewed pharmacological research.
Independently reviewed and fact-checked by the iMedic Medical Review Board, comprising board-certified specialists in dental anesthesiology and clinical pharmacology.
All medical claims are supported by Level 1A evidence (systematic reviews, meta-analyses, and randomized controlled trials) following the GRADE evidence framework.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest.